Revenue rises, but quarterly loss increases from June

Compliance View source PDF Explain this filing

KREBSBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.6%Reaction day

₹58.00

prior close

₹57.33

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.5%-0.1% vs market

Pharmaceuticals peers, median of 173sector-0.8%-1.8% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+1.7

15m

+1.7

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.6-2.5-0.1-0.8-1.8

Next day

-4.9-1.1-3.8-0.7-4.2

-4.7-0.8-3.8-0.5-4.2

-1.6+1.3-2.9+0.4-1.9

-0.3+2.5-2.8+1.4-1.7

-0.9pendingpending+1.4-2.2

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the quarter ended September 2026, operating income rose to Rs 582.77 lakh from Rs 417.41 lakh a year earlier but fell from Rs 714 lakh in June 2026. Net loss was Rs 539.85 lakh versus Rs 614.28 lakh a year ago and Rs 248.48 lakh in June. The half-year loss narrowed to Rs 788.33 lakh from Rs 1,146.71 lakh. EPS was negative Rs 2.50 for the quarter.

Likely market impact

Higher year-on-year revenue and a smaller half-year loss are positive, but continued losses and negative EPS may keep the stock under pressure.